LITHIUM LEVELS IN BIPOLAR ILLNESS

这项研究(已经进入五年中的第四年，我们 正在请求额外四年的支持)旨在 解决和解决有关以下问题的尚未解答的问题 低于标准范围的效果和有效性 锂(0.4~0.6mEq/1)在患者维持治疗中的应用 患有躁郁症。我们在比较和对比 这个较低的水平与更标准的水平(0.8-1.0mEq/1) 关于预防复发，存在不那么严重的 情感症状，以及与有害和有毒的联系 效果。这项双盲研究是同时进行的 马萨诸塞州综合医院和长岛 犹太人-希尔赛德医疗保险中心。预计吸纳量为 在两个地点完成175名受试者，与患者一起 随机分配到两种不同的治疗方案。

This study (which is in its fourth of five years, and for which we are requesting four additional years of support) is designed to address and resolve as-yet unanswered questions about the effects and effectiveness of a lower-than-standard range of lithium (0.4-0.6 mEq/1) in the maintenance treatment of patients with bipolar affective illness. We are comparing and contrasting this lower level with a more standard one (0.8-1.0 mEq/1) regarding protection against relapse, the presence of less severe affective symptoms, and association with unwanted and toxic effects. This double-blind study is being run concomitantly at both the Massachusetts General Hospital and the Long Island Jewish-Hillside Medicare Center. Projected intake to completion is 175 subjects at the two sites, with patients randomly assigned to the two different treatment regimens.